Medical Decision Making: Getting Started Primer On Medical Decision Analysis: Part 1
Medical Decision Making: Getting Started Primer On Medical Decision Analysis: Part 1
Medical Decision Making: Getting Started Primer On Medical Decision Analysis: Part 1
http://mdm.sagepub.com/
Allan S. Detsky, Gary Naglie, Murray D. Krahn, David Naimark and Donald A. Redelmeier
Med Decis Making 1997 17: 123
DOI: 10.1177/0272989X9701700201
The online version of this article can be found at:
http://mdm.sagepub.com/content/17/2/123
Published by:
http://www.sagepublications.com
On behalf of:
Additional services and information for Medical Decision Making can be found at:
Email Alerts: http://mdm.sagepub.com/cgi/alerts
Subscriptions: http://mdm.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav
Citations: http://mdm.sagepub.com/content/17/2/123.refs.html
Tutorial:
How to
Perform
Decision
Analysis
Analysis:
1—Getting Started
learned has
to
develop
come
working
ysis.
When Is Decision
Analysis Appropriate?
toronto.edu).
123
124
not
perform
decision
analysis of
question. However,
clearly supported by
are
direct evidence.
Sometimes randomized trials have been performed but the optimal decision remains uncertain
because several outcomes are involved. The randomized trials of anticoagulation in atrial fibrillation, for example, show a reduction in the risk of
stroke but an increased risk of bleeding and, in
some trials, a considerable dropout because patients
do not wish to be on coumadin for indefinite periods of time. A decision analysis20 can incorporate
these three outcomes as well as possible different
levels of risk depending on patient characteristics
(e.g., age, other existing cardiac disease). Such a
model can help the decision maker understand the
not as
re-
technique (such
as
echocardiography) compared
with an equally accurate but more invasive diagnostic technique (such as angiography) for assessing
myocardial wall motion or thickness. Of course, decision-analytic models can also be used to estimate
the cost-effectiveness of interventions involving
dual outcomes such as costs and utilities. In this
circumstance, one strategy may clearly be better
than the other in the clinical sense but result in
higher expected costs. In this series, however, we
focus on models that have only one clinical outcome
measure.
A second
ity of data. In
develop
complex
more
nature of the
options
to
those that
are
clearly different from each other and cover the spectrum of the problem. Thus, one might consider only
three options in the pulmonary embolism example:
doing nothing further, anticoagulating without further tests, and performing a ventilation-perfusion
lung scan and going on to angiography only if its
result is neither clearly positive (high-probability
scan) nor clearly negative (normal scan). One can
always
add other
options
later
on.
Time Frame
In comparing outcomes of alternative strategies,
the analyst must determine an appropriate time
frame. When
or
In
choosing
an
appropriate
time
depend upon
frame,
one con-
fronts the same tradeoff as noted in the above section on accuracy versus simplicity, namely desire for
completeness versus availability of data. Most clinical studies including randomized trials have relatively limited time frames. Even for trials involving
chronic diseases such as coronary artery disease,
the period of observation is usually between one and
three years and rarely as long as five years. Occasionally one gets reports of long-term follow-up, but
125
the observation periods in these reports rarely exceed ten years.22 Some cohort studies, such as the
Framingham Study, have much longer periods of
observation. One, therefore, must balance the desire
for complete long-term follow-up with the availability of valid and precise data. Most analysts will have
to extend the period of observation of a randomized
trial for their analysis and therefore will have to extrapolate the data. The performance of extensive
sensitivity analyses around these extrapolations is
References
HJ, Detsky AS, Armstrong PW Management of asymp-
function:
decision
401.
2. Krahn M,
Naylor CD,
1991;115:248-55.
UD, Guerriere M, Read SE, Detsky AS. Percutaneous
injuries among health care workers: the real value of HIV
testing of "donor" blood. Arch Intern Med. 1991;151:2033-
3. Allen
Krahn MD, Naimark D, Redelmeier, Detsky AS. Primedical decision analysis: Part 3—estimating probabilities and utilities. Med Decis Making. 1997;17.136-41.
12. Krahn MD, Naglie G, Naimark D, Redelmeier D, Detsky AS
Primer on medical decision analysis: Part 4—analyzing the
model and interpreting the results. Med Decis Making. 1997;
11
17:142-51.
13
esophagogastrectomy
with
without
or
drainage?
18.
analysis.
J Rheumatol.
pneumonia
decision
analysis
Am Rev
Respir
Dis
Endarterectomy Trial
20
1993;148:370-7
Barrett BJ, Parfrey PS, Foley RN, Detsky AS. An economic
analysis
of
strategies
for the
use
Making.
diag-
1994,14
Carotid
22.
JV, Biem HJ, Detsky AS Bronchoscopy vs empirical therapy in HIV-infected patients with presumptive Pneumocystis
Symptomatic
1992,19.
7. Tu
Phil-
PA: W. B.
1220-8.
Analysis.
Saunders, 1980.
Sox H, Blatt MA, Higgins MC, Marton KI. Medical Decision
Making. London, England: Butterworth & Co., 1988.
adelphia,
21
9-13
6. Buchbinder R, Detsky AS.
cell arteritis. a decision
JAMA 1995,273.1610-3.
MC, Fineberg HV. Clinical Decision
cability
17 Weinstein
Ann
carimi
Naglie G,
mer on
40.
4.
2—building a tree.
14.
important.
1. Biem
Glossary
Markov Model: A decision-analytic model that involves a Markov process, a modeling technique derived from matrix alge-
tervals
or
transitions
cycles.
during